Novavax COVID vaccine gets backing of U.S. FDA advisers

By Reuters
Illustration of COVID-19 vaccine vial
A vial labelled "Novavax COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
June 7 (Reuters) - Advisers to the U.S. Food and Drug Administration on Tuesday voted to recommend authorization of Novavax Inc's (NVAX.O), opens new tab COVID-19 vaccine for adults.

Sign up here.

Reporting by Manas Mishra in Bengaluru Editing by Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Purchase Licensing Rights

Read Next